Litcius/Paper detail

The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review

Jennifer R. Landes, Stephen A. Moore, Brooke Bartley, Hung Q. Doan, Peter L. Rady, Stephen K. Tyring

2022Journal of Cancer Research and Clinical Oncology40 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCancerClinical trialHematologyMultiple myelomaCancer researchOncologyInternal medicineSelenium in Biological SystemsNuclear Structure and FunctionCancer, Lipids, and Metabolism
The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review | Litcius